Cargando…

Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers

Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a leading cause of death among men worldwide. Despite extensive efforts in biomarker discovery during the last years, currently used clinical biomarkers are still lacking enough specificity and sensitivity for PCa early detect...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Cebrián, Nuria, Rojas-Benedicto, Ayelén, Albors-Vaquer, Arturo, López-Guerrero, José Antonio, Pineda-Lucena, Antonio, Puchades-Carrasco, Leonor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468766/
https://www.ncbi.nlm.nih.gov/pubmed/30857149
http://dx.doi.org/10.3390/metabo9030048
_version_ 1783411509042348032
author Gómez-Cebrián, Nuria
Rojas-Benedicto, Ayelén
Albors-Vaquer, Arturo
López-Guerrero, José Antonio
Pineda-Lucena, Antonio
Puchades-Carrasco, Leonor
author_facet Gómez-Cebrián, Nuria
Rojas-Benedicto, Ayelén
Albors-Vaquer, Arturo
López-Guerrero, José Antonio
Pineda-Lucena, Antonio
Puchades-Carrasco, Leonor
author_sort Gómez-Cebrián, Nuria
collection PubMed
description Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a leading cause of death among men worldwide. Despite extensive efforts in biomarker discovery during the last years, currently used clinical biomarkers are still lacking enough specificity and sensitivity for PCa early detection, patient prognosis, and monitoring. Therefore, more precise biomarkers are required to improve the clinical management of PCa patients. In this context, metabolomics has shown to be a promising and powerful tool to identify novel PCa biomarkers in biofluids. Thus, changes in polyamines, tricarboxylic acid (TCA) cycle, amino acids, and fatty acids metabolism have been reported in different studies analyzing PCa patients’ biofluids. The review provides an up-to-date summary of the main metabolic alterations that have been described in biofluid-based studies of PCa patients, as well as a discussion regarding their potential to improve clinical PCa diagnosis and prognosis. Furthermore, a summary of the most significant findings reported in these studies and the connections and interactions between the different metabolic changes described has also been included, aiming to better describe the specific metabolic signature associated to PCa.
format Online
Article
Text
id pubmed-6468766
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64687662019-04-22 Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers Gómez-Cebrián, Nuria Rojas-Benedicto, Ayelén Albors-Vaquer, Arturo López-Guerrero, José Antonio Pineda-Lucena, Antonio Puchades-Carrasco, Leonor Metabolites Review Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a leading cause of death among men worldwide. Despite extensive efforts in biomarker discovery during the last years, currently used clinical biomarkers are still lacking enough specificity and sensitivity for PCa early detection, patient prognosis, and monitoring. Therefore, more precise biomarkers are required to improve the clinical management of PCa patients. In this context, metabolomics has shown to be a promising and powerful tool to identify novel PCa biomarkers in biofluids. Thus, changes in polyamines, tricarboxylic acid (TCA) cycle, amino acids, and fatty acids metabolism have been reported in different studies analyzing PCa patients’ biofluids. The review provides an up-to-date summary of the main metabolic alterations that have been described in biofluid-based studies of PCa patients, as well as a discussion regarding their potential to improve clinical PCa diagnosis and prognosis. Furthermore, a summary of the most significant findings reported in these studies and the connections and interactions between the different metabolic changes described has also been included, aiming to better describe the specific metabolic signature associated to PCa. MDPI 2019-03-08 /pmc/articles/PMC6468766/ /pubmed/30857149 http://dx.doi.org/10.3390/metabo9030048 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gómez-Cebrián, Nuria
Rojas-Benedicto, Ayelén
Albors-Vaquer, Arturo
López-Guerrero, José Antonio
Pineda-Lucena, Antonio
Puchades-Carrasco, Leonor
Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
title Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
title_full Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
title_fullStr Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
title_full_unstemmed Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
title_short Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
title_sort metabolomics contributions to the discovery of prostate cancer biomarkers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468766/
https://www.ncbi.nlm.nih.gov/pubmed/30857149
http://dx.doi.org/10.3390/metabo9030048
work_keys_str_mv AT gomezcebriannuria metabolomicscontributionstothediscoveryofprostatecancerbiomarkers
AT rojasbenedictoayelen metabolomicscontributionstothediscoveryofprostatecancerbiomarkers
AT alborsvaquerarturo metabolomicscontributionstothediscoveryofprostatecancerbiomarkers
AT lopezguerrerojoseantonio metabolomicscontributionstothediscoveryofprostatecancerbiomarkers
AT pinedalucenaantonio metabolomicscontributionstothediscoveryofprostatecancerbiomarkers
AT puchadescarrascoleonor metabolomicscontributionstothediscoveryofprostatecancerbiomarkers